Blueprint Medicines (BPMC) Tops Q4 EPS by 34c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Blueprint Medicines (BPMC) Tops Q4 EPS by 34c

Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results

February 13, 2020 7:00 AM EST

CAMBRIDGE, Mass., Feb. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2019.

"In 2020, we will complete our evolution into a fully-integrated global biopharmaceutical company and fortify our leadership in the field of... More